Johnson & Johnson (JNJ) Tops Q3 EPS by 3c; Boosts FY11 Outlook
Tweet
Share
E-mail
Get Alerts JNJ Hot Sheet
Join SI Premium – FREE
Johnson & Johnson (NYSE: JNJ) reported Q3 EPS of $1.24, $0.03 better than the analyst estimate of $1.21. Revenue for the quarter came in at $16 billion versus the consensus estimate of $16.02 billion.
Johnson & Johnson sees FY2011 EPS of $4.95-$5.00, versus the consensus of $4.96. The company had previously guided to $4.90-$5.
Johnson & Johnson sees FY2011 EPS of $4.95-$5.00, versus the consensus of $4.96. The company had previously guided to $4.90-$5.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Globant (GLOB) Misses Q2 EPS by 10c, Offers Guidance
- Acurx Pharmaceuticals (ACXP) Tops Q2 EPS by 4c
- Blackhawk Network (HAWK) Reports Q2 Loss of $0.07; Offers Guidance
Create E-mail Alert Related Categories
Earnings, Guidance, Hot Earnings, Hot GuidanceSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
